Navigation Links
NEWSLETTER: Antibody Fragment Production Breakthrough with 2nd Generation EBA
Date:5/12/2009

Hamburg, Germany and Copenhagen, Denmark, May 12th, 2009 / b3c newswire / – Richter-Helm BioLogics GmbH & Co. KG announces today a technological breakthrough in the field of purification of antibody fragments from an E. coli expression system. Richter-Helm BioLogics has finalized the downstream process for Phase III clinical trial material using 2nd Generation Expanded Bed Adsorption (EBA) technology developed by the Danish biotech company Upfront Chromatography A/S.

Having conducted a series of tests, Richter-Helm has discovered significant advantages of 2nd Generation EBA over the latest, alternative chromatographic methods. A 60% increase in yield was observed using direct capture.  The simplified process is less likely to cause processing problems.  The processing time to take product from homogenate to clarified, partially purified material was reduced to one working day, decreasing the possibility of product degradation.  The volume of buffers required to perform clarification and capture was reduced significantly, effecting cost of manufacture.

Upfront’s innovation lay in the usage of higher density adsorbents and the proprietary design of an operational system which provides increased flow rates and is free from clogging and channel formation.

Rhobust® has improved Richter-Helm’s offering to customers operating with microbial derived products, providing a superior downstream process for clinical manufacturing. Richter-Helm embraced this technology under tight timelines and cost pressures and has been rewarded with a superior downstream offering in the CMO market.

The Rhobust® universal processing platform from Upfront Chromatography enables customers to efficiently capture and purify monoclonal antibodies, therapeutic proteins and other biomolecules directly from blood plasma or bioreactors, without the need for prior filtration.  

Selection of proprietary mixed mode ligand chemistry enables efficient control of the capture and release of target molecules by simple changes of pH, which can be readily implemented in large-scale production facilities and maintain biological activity of the product. Mixed mode ligands are selected for their suitability for industrial processing, in particular their stability during high temperature cleaning with 1M NaOH, low toxicity, and very low leakage from adsorbent.


For further information please contact:

Richter-Helm:
Dr. Kai Pohlmeyer
Head of Business Development
Phone: +49-40-2375-2430  
Mail: k.pohlmeyer@richter-helm-biotec.eu

--> Meet us at Bio2009 Booth number 5222


Upfront :
Rob Noel
Global Manager
Business Development
Phone: +44 7970 930895,
Mail: robnoel@upfront-dk.com

Natalya Clark
Marketing/PR Manager
Phone:.+4539174337
Mail: nac@upfront-dk.com

--> Meet us at Bio2009 Booth number 5123 BioProcess Zone 


'/>"/>
b3c newswire

Related biology news :

1. Novel antibody prevents infection by hepatitis C virus
2. Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck
3. Antibody key to treating variant CJD, scientists find
4. UC San Diego and Genentech scientists develop potentially disruptive antibody sequencing technology
5. ETH Zurich researchers develop antibody test
6. Bright lights: Mystery of glowing antibody solved by Scripps research scientists
7. Yale chemist receives NIH Young Investigator Award for antibody targeting
8. Reversing cognitive deficits: Injectable antibody may attack source of problem
9. Fossil fragments reveal 500-million-year-old monster predator
10. The song doesnt remain the same in fragmented bird populations
11. EMBL scientists develop first fully automated pipeline for multiprotein complex production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... 2017 , ... At its national board meeting in North ... the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology and ... ARCS Alumni Hall of Fame . ASTER Labs is a technology development ...
(Date:10/11/2017)... Wayne. NJ (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a ... rinse one eye at a time. So which eye do you rinse first if a ... you have Plum Duo Eye Wash with its unique dual eye piece. , ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... will be hosting a Webinar titled, “Pathology is going digital. Is your lab ... digital pathology adoption best practices and how Proscia improves lab economics and realizes ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
Breaking Biology Technology: